Scholarlink

Background <p>This study investigated the role of high-density lipoprotein (HDL) in older patients with schizophrenia (SCZ), examining its associations with clinical symptoms, cognitive function, and other conventional lipid parameters (triglycerides, total cholesterol), as well as its longitudinal changes during a 6-month follow-up period under routine clinical care.</p> Methods <p>A total of 77 participants (30 healthy controls [HC] and 47 SCZ patients) were stratified into high- and low-HDL subgroups based on a cutoff of 0.91 mmol/L. Baseline comparisons revealed significantly lower HDL levels in the SCZ group compared to HC. The SCZ group, as expected, exhibited significant psychopathology (assessed by PANSS) and impaired cognitive performance across multiple RBANS domains.</p> Results <p>HDL subgroup analysis demonstrated that among SCZ patients, the high-HDL subgroup exhibited higher PANSS scores and worse performance in specific delayed memory domains compared to the low-HDL subgroup. In SCZ patients, correlation analysis showed a positive association between HDL and PANSS scores (<i>r</i> = 0.28, <i>p</i> &lt; 0.05) and a negative correlation with performance in one delayed memory task (Figure Recall: <i>r</i> = -0.30, <i>p</i> = 0.04). Longitudinal follow-up after 6 months in the SCZ group revealed a reduction in HDL levels (though not statistically significant), along with decreased PANSS scores and improved RBANS total scores.</p> Conclusion <p>These findings reveal a complex relationship between HDL and SCZ. While SCZ patients have lower HDL than healthy controls, within the patient group, higher HDL levels were paradoxically associated with greater symptom severity and poorer memory performance. This suggests that in older patients with chronic SCZ, the functional quality of HDL may be more critical than its absolute concentration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-density lipoprotein (HDL) in older patients with schizophrenia: implications for clinical and cognitive outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Shuyan Chen,
  • Jiaquan Liang,
  • Cuiyun Li,
  • Chunjie Lin,
  • Weiming Li,
  • Zhencheng He,
  • Fangcheng Fan,
  • Shujuan Zhang

摘要

Background

This study investigated the role of high-density lipoprotein (HDL) in older patients with schizophrenia (SCZ), examining its associations with clinical symptoms, cognitive function, and other conventional lipid parameters (triglycerides, total cholesterol), as well as its longitudinal changes during a 6-month follow-up period under routine clinical care.

Methods

A total of 77 participants (30 healthy controls [HC] and 47 SCZ patients) were stratified into high- and low-HDL subgroups based on a cutoff of 0.91 mmol/L. Baseline comparisons revealed significantly lower HDL levels in the SCZ group compared to HC. The SCZ group, as expected, exhibited significant psychopathology (assessed by PANSS) and impaired cognitive performance across multiple RBANS domains.

Results

HDL subgroup analysis demonstrated that among SCZ patients, the high-HDL subgroup exhibited higher PANSS scores and worse performance in specific delayed memory domains compared to the low-HDL subgroup. In SCZ patients, correlation analysis showed a positive association between HDL and PANSS scores (r = 0.28, p < 0.05) and a negative correlation with performance in one delayed memory task (Figure Recall: r = -0.30, p = 0.04). Longitudinal follow-up after 6 months in the SCZ group revealed a reduction in HDL levels (though not statistically significant), along with decreased PANSS scores and improved RBANS total scores.

Conclusion

These findings reveal a complex relationship between HDL and SCZ. While SCZ patients have lower HDL than healthy controls, within the patient group, higher HDL levels were paradoxically associated with greater symptom severity and poorer memory performance. This suggests that in older patients with chronic SCZ, the functional quality of HDL may be more critical than its absolute concentration.